Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Barbara Ann Karmanos Cancer Institute
Study ID
NCT01812668
Status
Completed

Conditions

  • Adenocarcinoma of the Prostate
  • Hormone-resistant Prostate Cancer
  • Recurrent Prostate Cancer
  • Stage IV Prostate Cancer

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • cabozantinib-s-malate — DRUG
    Given PO
  • fluorine F 18 d-FMAU — RADIATION
    Undergo 18F PET/FMAU PET scan
  • positron emission tomography — PROCEDURE
    Undergo 18F PET/FMAU PET scan
  • pharmacological study — OTHER
    Correlative studies
  • laboratory biomarker analysis — OTHER
    Correlative studies

Study Details

This pilot clinical trial studies cabozantinib-s-malate in treating patients with hormone-resistant metastatic prostate cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

Key Dates

Start date
Mar 31, 2013
Status verified
Aug 2021
Primary completion
Jan 18, 2019
Completion
Jun 18, 2019

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (cabozantinib-s-malate)
    Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. [ Time Frame: Baseline to 4 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Barbara Ann Karmanos Cancer InstituteDetroitMichigan48201-

Find similar trials in Detroit, MI

By research site
Barbara Ann Karmanos Cancer Institute· Detroit, MI

Related Studies